Sichuan Biokin Pharmaceutical (SHA:688506) said its bispecific antibody-drug conjugate Lunkan Yilongtuo met the primary endpoint in the third-phase trial for non-small cell lung cancer.
The trial met its primary endpoint of progression-free survival, with a favorable trend in overall survival, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 2% in recent trade.